These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Recombinant adeno-associated virus as delivery vector for gene therapy--a review. Lu Y Stem Cells Dev; 2004 Feb; 13(1):133-45. PubMed ID: 15068701 [TBL] [Abstract][Full Text] [Related]
8. Optimizing the adeno-associated viral vector system: a brief summary. Hacker U; Büning H Ther Deliv; 2011 Aug; 2(8):967-70. PubMed ID: 22826865 [TBL] [Abstract][Full Text] [Related]
9. Adeno-associated virus capsid protein expression in Escherichia coli and chemically defined capsid assembly. Le DT; Radukic MT; Müller KM Sci Rep; 2019 Dec; 9(1):18631. PubMed ID: 31819093 [TBL] [Abstract][Full Text] [Related]
10. Stability and compatibility of recombinant adeno-associated virus under conditions commonly encountered in human gene therapy trials. Gruntman AM; Su L; Su Q; Gao G; Mueller C; Flotte TR Hum Gene Ther Methods; 2015 Apr; 26(2):71-6. PubMed ID: 25819833 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Davidoff AM; Gray JT; Ng CY; Zhang Y; Zhou J; Spence Y; Bakar Y; Nathwani AC Mol Ther; 2005 Jun; 11(6):875-88. PubMed ID: 15922958 [TBL] [Abstract][Full Text] [Related]
12. Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials with Recombinant Adeno-Associated Viral Vectors: An Evolving Controversy. Ertl HCJ; High KA Hum Gene Ther; 2017 Apr; 28(4):328-337. PubMed ID: 28042943 [TBL] [Abstract][Full Text] [Related]
13. Ocular gene therapy: an evaluation of recombinant adeno-associated virus-mediated gene therapy interventions for the treatment of ocular disease. Roy K; Stein L; Kaushal S Hum Gene Ther; 2010 Aug; 21(8):915-27. PubMed ID: 20384478 [TBL] [Abstract][Full Text] [Related]
14. Immune responses to adeno-associated virus and its recombinant vectors. Sun JY; Anand-Jawa V; Chatterjee S; Wong KK Gene Ther; 2003 Jun; 10(11):964-76. PubMed ID: 12756417 [TBL] [Abstract][Full Text] [Related]
15. A new method for recombinant adeno-associated virus vector delivery to murine diaphragm. Mah C; Fraites TJ; Cresawn KO; Zolotukhin I; Lewis MA; Byrne BJ Mol Ther; 2004 Mar; 9(3):458-63. PubMed ID: 15006614 [TBL] [Abstract][Full Text] [Related]
16. Bound Protein- and Peptide-Based Strategies for Adeno-Associated Virus Vector-Mediated Gene Therapy: Where Do We Stand Now? Zhang X; Chai Z; Samulski RJ; Li C Hum Gene Ther; 2020 Nov; 31(21-22):1146-1154. PubMed ID: 32940063 [TBL] [Abstract][Full Text] [Related]
17. Vectrology of adeno-associated viruses (AAV). Skubis-Zegadło J; Stachurska A; Małecki M Med Wieku Rozwoj; 2013; 17(3):202-6. PubMed ID: 24296444 [TBL] [Abstract][Full Text] [Related]
18. Machine-learning-guided Directed Evolution for AAV Capsid Engineering. Fu X; Suo H; Zhang J; Chen D Curr Pharm Des; 2024; 30(11):811-824. PubMed ID: 38445704 [TBL] [Abstract][Full Text] [Related]
19. rAAV vector-mediated gene therapy for experimental ischemic stroke. Li ZJ; Wang RZ Neurol India; 2008; 56(2):116-21. PubMed ID: 18688133 [TBL] [Abstract][Full Text] [Related]
20. Adenovirus and adeno-associated virus vectors. Lai CM; Lai YK; Rakoczy PE DNA Cell Biol; 2002 Dec; 21(12):895-913. PubMed ID: 12573049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]